RAMM Pharma Corp.
RAMM
CNSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -77.04% | -77.94% | -41.64% | -27.13% | -28.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.04% | -77.94% | -41.64% | -27.13% | -28.92% |
| Cost of Revenue | -90.73% | -89.78% | -73.89% | 49.94% | -12.45% |
| Gross Profit | -13.18% | -36.07% | -10.74% | -99.93% | -62.15% |
| SG&A Expenses | -0.16% | -22.00% | -56.20% | -42.30% | -56.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -44.23% | -70.27% | -35.80% | -26.67% | -21.21% |
| Total Operating Expenses | -38.04% | -46.02% | -57.59% | -17.92% | -44.65% |
| Operating Income | -1.79% | 19.63% | 61.76% | 6.98% | 54.85% |
| Income Before Tax | -153.32% | 28.52% | 38.72% | 47.54% | 93.75% |
| Income Tax Expenses | -- | -- | 30.51% | -- | -- |
| Earnings from Continuing Operations | -38.73% | 22.28% | 38.67% | 47.54% | 88.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.73% | 22.28% | 38.67% | 47.54% | 88.58% |
| EBIT | -1.79% | 19.63% | 61.76% | 6.98% | 54.85% |
| EBITDA | -23.90% | 11.04% | 63.93% | -14.19% | 59.78% |
| EPS Basic | -41.67% | 21.67% | 38.64% | 47.54% | 88.79% |
| Normalized Basic EPS | 52.17% | 7.32% | 34.67% | 44.74% | 65.67% |
| EPS Diluted | -41.67% | 21.67% | 38.64% | 47.54% | 88.79% |
| Normalized Diluted EPS | 52.17% | 7.32% | 34.67% | 44.74% | 65.67% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |